Steven Cohen's COGT Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 827,525 shares of Cogent Biosciences, Inc. (COGT) worth $29.39 M, representing 0.03% of the portfolio. First purchased in 2020-Q4, this long-term strategic position has been held for 21 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in COGT, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2024, adding 3.79 M shares. Largest reduction occurred in Q4 2024, reducing 5.12 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Cogent Biosciences (COGT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cogent Biosciences (COGT) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -410,308 | Reduce 33.15% | 827,525 | $35.52 |
| Q3 2025 | -3.67 M | Reduce 74.80% | 1.24 M | $14.36 |
| Q2 2025 | -383,621 | Reduce 7.24% | 4.91 M | $7.18 |
| Q1 2025 | -51,757 | Reduce 0.97% | 5.3 M | $5.99 |
| Q4 2024 | -5.12 M | Reduce 48.93% | 5.35 M | $7.80 |
| Q2 2024 | +3.79 M | Add 56.83% | 10.47 M | $8.43 |
| Q1 2024 | +1.48 M | Add 28.60% | 6.68 M | $6.72 |
| Q4 2023 | +1.42 M | Add 37.82% | 5.19 M | $5.88 |
| Q3 2023 | -918,299 | Reduce 19.60% | 3.77 M | $9.75 |
| Q2 2023 | +2.45 M | Add 109.46% | 4.69 M | $11.84 |
| Q1 2023 | +2.24 M | New Buy | 2.24 M | $10.79 |
| Q4 2022 | -357,200 | Sold Out | 0 | $0.00 |
| Q3 2022 | +357,200 | New Buy | 357,200 | $14.92 |
| Q2 2022 | -853,451 | Sold Out | 0 | $0.00 |
| Q1 2022 | -13,449 | Reduce 1.55% | 853,451 | $7.49 |
| Q4 2021 | -138,403 | Reduce 13.77% | 866,900 | $8.58 |
| Q3 2021 | -477,792 | Reduce 32.22% | 1.01 M | $8.41 |
| Q2 2021 | +871,595 | Add 142.53% | 1.48 M | $8.11 |
| Q1 2021 | +206,500 | Add 50.99% | 611,500 | $8.78 |
| Q4 2020 | +405,000 | New Buy | 405,000 | $11.23 |
Steven Cohen's Cogent Biosciences Investment FAQs
Steven Cohen first purchased Cogent Biosciences, Inc. (COGT) in Q4 2020, acquiring 405,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Cogent Biosciences, Inc. (COGT) for 21 quarters since Q4 2020.
Steven Cohen's largest addition to Cogent Biosciences, Inc. (COGT) was in Q2 2024, adding 10,470,398 shares worth $88.27 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 827,525 shares of Cogent Biosciences, Inc. (COGT), valued at approximately $29.39 M.
As of the Q4 2025 filing, Cogent Biosciences, Inc. (COGT) represents approximately 0.03% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Cogent Biosciences, Inc. (COGT) was 10,470,398 shares, as reported at the end of Q2 2024.